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ABSTRACT
Because of intra- and interindividual variability, bioavailability, and pharmacokinetics of busulfan (Bu) in chil-
dren, oral busulfan without therapeutic drug monitoring (TDM) is assumed to be associated with higher graft
failure rates as well as higher toxicity (eg, veno-occlusive disease [VOD]). This study compares the outcome
of hematopoietic stem cell transplantation (HSCT) of 2 groups: 1) 30 patients who received myeloablation
with once-daily intravenous (i.v.) dose-targeted busulfan (BUdtIV) based on TDM and 2) 30 patients who re-
ceived the current practice of untargeted oral busulfan (BUPO). Patients received a 3-hour infusion of Bu at
a first dose of 120 mg/m2 (age $1 year) or 80 mg/m2 (\1 year), or BUPO 1 mg/kg 4 times daily. Both regimens
were continued for 4 days. The target area under the curve (AUC)was defined as 17,500 mg*h/l. BUdtIV resulted
in higher event-free survival (EFS) and survival rates compared to BUPO (EFS: 30% versus 83%, P\ .001, sur-
vival: 53% versus 83%, P5 .016). BUdtIV was associated with more cases of VOD. TDMwas feasible in routine
clinical practice. The results show that i.v. Bu using TDM is preferable over oral Bu in children undergoing al-
logeneic stem cell transplantation, especially in those at high risk for graft failure/relapse.
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Busulfan (Bu) is an alkylating agent that has been
used since the 1950s. Currently, Bu is one of the
most frequently used chemotherapeutic agents in
high-dose preparative chemotherapy combination
regimens. It can serve as an alternative to total body ir-
radiation (TBI) in patients undergoing hemopoietic
stem cell transplantation (HSCT) for various malig-
nant and nonmalignant diseases [1,2,3].
Until recently, Bu was only available in an oral
form and was given 4 times daily. Although Bu was88shown to be effective when used in this regimen, the
therapeutic potential of the oral drug has been com-
promised owing to unpredictable exposure, especially
in children [2,4,5]. To reduce both intra- and interin-
dividual variability of Bu pharmacokinetics (PK), i.v.
formulations of Bu have recently been developed. In
adults, i.v. Bu showed predictable and consistent phar-
macokinetic profiles with acceptable toxicity [6-11]. In
children, however, interindividual variance of PK pro-
files after i.v. dosing of Bu remained rather high [12].
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posure is associated with toxicity, such as the develop-
ment of veno-occlusive disease (VOD) [2,13-15],
whereas underexposure to Bu was found to be associ-
ated with an increased incidence of graft rejection or
relapse [16,17]. This appears to be even more impor-
tant in diseases known to be associated with high graft
failure/relapse rates resulting in a lower event-free sur-
vival (EFS), such as inborn error of metabolism (IEM),
myelodysplastic syndrome (MDS) and hemophago-
cytic lympho-histiocytosis (HLH) [18-22] Dose tar-
geting based on therapeutic drug monitoring (TDM)
improved clinical outcome in pediatric HSCT recipi-
ents [3,5,23,24]. For these reasons, the use of an i.v.
formulation of Bu combined with dose targeting based
on TDM (BUdtIV) might have advantages over oral
dosing without dose targeting (BUPO) in children.
Thus far, Bu (p.o. and i.v.) is mainly given 4 times
daily [1,5,7,11,14,15,23-26]. However, once-daily
dosing is possible and would be much more conve-
nient for the patient and caregivers. In addition, it
can be hypothesized that reducing the exposure period
to Bu might be associated with reduced toxicity. The
use of once-daily dosing could allow enzyme recovery
of glutathione-S-reductase and glutathione-S-trans-
ferase between doses. As a result, no accumulation of
Bu would occur. A decrease of the dosing frequency
of Bu showed similar or decreased toxicity (VOD) in
adults [27-29].
This study used a once daily i.v. dose of Bu and tar-
geted for an ‘‘area under the curve’’ (AUC) of 17.500
mg*h/l (4263 mmol*min/l). This target was based
on past literature (of 4 times daily dosing)
[9,10,12,25,30]. Comparison was made between the
outcome of HSCT in children after a myeloablative
preparative chemotherapyregimen including BudtIV
and the current practice of untargeted oral Bu.
MATERIALS AND METHODS
Study Population
In July 2003, this study’s researchers replaced oral
Bu with BudtIV based on TDM. The effects on out-
come were studied after the inclusion of 30 patients
with BudtIV. Outcomes were compared with the 30
most recent patients receiving oral Bu. BudtIV was
gradually introduced, starting with nonmalignant indi-
cations known to be associated with high graft-failure
rates (ie, inborn error of metabolism [IEM]), followed
by immune deficiency patients and, finally, patients
with malignancies. In December 2004, the first IEM
patient received BUdtIV. In the University Medical
Center Utrecht (UMCU), all patients undergoing
HSCT are prospectively included in a research data-
base. All patients who were treated with Bu (p.o. or
i.v. combined with TDM) from July 2003 until March
2007, were included in this study. Patients were en-rolled in the HSCT protocol and research protocol af-
ter giving their written informed consent.
Transplantation Details, Conditioning Regimens
and Supportive Care
Human leukocyte antigen-matching (HLA-
matching) was based on high-resolution (HR)-typing
for class I and class II (10 antigens) for family and un-
related bone marrow (BM) or peripheral blood stem
cell (PBSC) donor. For cord blood (CB)-donors, lower
resolution criteria were used (ie intermediate resolu-
tion for loci A and B and major histocompatibility
complex, class II, DR beta 1 (DRB1) by HR-typing).
A DPB1 mismatch was not taken into account. For
the analyses, patients were divided into a matched
and mismatched group. CB-grafts, which were identi-
cal according to the lower resolution criteria men-
tioned above, were regarded as matched (6 antigens).
Bu (Busilvex Pierre Fabre Medicament, Bou-
logne, France) was given as an i.v. infusion during 3
hours once daily for 4 consecutive days. Patients older
than 1 year received a first dosage of 120 mg/m2; pa-
tients younger than 1 year received 80 mg/m2. TDM
was performed in these patients.
Bu seems to have an age independent correlation
between body surface area (BSA) and clearance in chil-
dren [12,31]. The clearance of drugs in newborns is
highly dependent on the pace of development of the
specific enzymes involved in metabolism or renal elim-
ination. Data on the pace of maturation of glutathione
S-transferase (the enzyme which metabolizes Bu) is
lacking [16]. Generally, most enzyme pathways have
matured after 1 year [32-37]. Therefore, the age of 1
year was chosen as a boundary between the 2 dosage
regimens in this study and a dosing schedule based
on BSA was used.
BUPO was given 1 mg/kg 4 times daily for 4 days
(total dose 16 mg/kg). Children younger than 3 years
received 1.25 mg/kg 4 times daily. No TDM was per-
formed nor was dosing adjusted to a target AUC in the
BUPO patients. All i.v. cystostatic medications were
prepared by the pharmacy.
In general, a combination of Bu, cyclophospha-
mide (Cy), and melphalan (Mel) was used for myeloid
malignancies (including MDS and infant acute lym-
phoblastic leukemia (ALL); Bu, Cy, and, in selected
cases, fludarabine (Flu) for nonmalignant indications;
and Bu, Cy and etoposide (VP16) for patients with
HLH, as well as for some younger patients with ALL
(\3 years). Patients with Fanconi anemia aremore vul-
nerable to chemotherapy. Therefore, the patients with
Fanconi anemia received a reduced dose and for the in-
travenous group they were targeted to a lower AUC
(total 30,000 mg*h/l) in addition to a reduced dose of
Cy (cumulative dose 40 mg/kg). Bu was given as first
agent followed by Cy after at least 24 hours and Mel,
Flu, or VP16. Unrelated donors received serotherapy
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(Genzyme) or alemtuzumab (Genzyme). Patients
treated for ALL received ATG-rabbit (Fresenius). As
supportive care, patients received antiemetic drugs;
prophylactic anticonvulsive therapy (clonazepam) dur-
ing Bu; and as antimicrobial prophylaxis, ciprofloxin,
fluconazol and acyclovir. As graft-versus-host disease
(GVHD) prophylaxis: cyclosporine was given in the
matched sibling donors; cyclosporine (CSP) plus
methotrexate (MTX) was given in the unrelated recip-
ients; and CSP plus prednisolon in the CB recipients.
Patients who received CB were treated with filgrastim
(Amgen Europe B.V.) from day 17 until neutrophils
were above 2000 /mL.
Target AUC and Therapeutic Drug Monitoring
The target AUC was defined as 17.500 mg*h/l
(4263 mmol*min/l) per day. On the second day of treat-
ment, dose adjustments based on AUC were per-
formed before the second dose.
The analysis by high pressure liquid chromotogra-
phy was based on the method previously described by
Zwaveling et al [11] and analyzed using a limited sam-
pling model established by Cremers et al [7,11].
Empirical Bayesian pharmacokinetic parameter esti-
mates (clearance and volume of distribution) were gen-
erated using the pharmacokinetic software package
MwPharm [38]. An one-compartment model was
used, based on the literature [7,11]. The AUC was cal-
culated from the expression dose/clearance and was
based on 3 blood samples: 1, 2 and 3 hours after the
end of infusion.
Treatment with i.v. Bu started at the first day at
9:00 AM. Blood samples were collected trough the lu-
men of the central catheter that was not used for Bu in-
fusion and taken at 1, 2 and 3 hours after the end of the
first infusion at day 1 and 4. In addition, a sample was
taken at 24 hours after the start of the first infusion.
After the inclusion of 17 patients, a small change in
the design of the dose targeting was introduced. If
a dose adjustment .25% was suggested, blood sam-
ples at day 2 (and if necessary on day 3) were collected.
If necessary, dose adjustments at day 3 and 4 were
performed.
End Points for Evaluation of Therapy
Primary end points were EFS, and survival after
HSCT with a follow-up of at least 6 months. EFS was
definedas ‘‘aliveandengraftedandnothavinga relapse.’’
Secondary end points were VOD and GVHD grade 2
or higher, and the feasibility of TDM was studied.
VODwas diagnosed according to the modified Se-
attle criteria: at least 2 of 3 symptoms (painful hepato-
megaly; unexplained weight gain of $5% from
baseline; and hyperbilirubinemia, ie bilirubin $34
mmol/l) present before day 21 after HSCT and afterexclusion of other possible causes. Severity of VOD
was graded according to Bearman et al [39]. VOD
was treated with defibrotide (25 mg/kg/day divided
in 4 doses per day). No patient received defibrotide
prophylactically.
VOD risk was defined according to criteria de-
scribed in VOD-DF prophylaxis study [40] (eg, Bu
and Mel in the conditioning, HLH, second ablative
conditioning, osteopetrosis, pre-existent liver disease).
Acute GVHD (aGVHD) was diagnosed and
graded according to Glucksberg et al [41]. Chimerism
of.95%was regarded as having full donor.Donor chi-
merism of .10% and\95% was regarded as mixed.
Statistical Analysis
The associations between the variables and the end
points were analyzed in univariable and multivariable
logistic regression analyses. Dichotomous outcomes
(eg, EFS: yes/no) were used as dependent and predic-
tors as independent variables. Univariable predictors
of outcome that were statistically significant (P \
.10) were selected for multivariable logistic regression
analysis. Results are expressed as odds ratios (OR) and
corresponding 95% confidence intervals (95% CI).
CIs not including 1 P\2.05) were considered statisti-
cally significant.
Time to event (primary end point) was analyzed
with Kaplan-Meier curves. Significances were ex-
pressed as Log-Rank.
Because there was no randomization, the study
employed ‘‘propensity score techniques’’ to adjust for
prognosis in comparability (chance to get a certain
treatment: BUPO versus BUdtIV) [42]. To calculate
the propensity score, logistic regression analysis was
used including the following variables: T cell depletion
(TCD), stem cell source, HLA-matching, indication,
and risk of VOD. The calculated propensity score
was included in multivariable analysis for the primary
endpoints to adjust for comparability. Statistical anal-
yses were performed using SPSS version 12.1 (SPSS,
Chicago, IL).
RESULTS
Patients’ Characteristics
In total, 61 patients were included in the study be-
tween July 2003 and March 2007. Ages ranged be-
tween 2 months and 21 years; body weight ranged
between 5 and 100 kg. Thirty patients received oral
Bu and 31 patients received i.v. Bu with TDM as
part of a myeloablative conditioning. For 1 patient in
the BUdtIV group, TDM was not possible. The labo-
ratory method to determine the concentration of the
busulfan monsters was not available at that time.
This patient was excluded from further analysis, as
she did not meet our inclusion criteria. The patients
in the BUdtIV and BUPO group were comparable
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HSCT (Table 1). TCD (CD31 cell in graft ranged
from 104 to 107/kg) was used more often in the
BUPO group andCBwas usedmore often in the BUd-
Table 1. Patient Characteristics
BUPO BUdtIV P-Value
Median age at HSCT (range)
in years
5 (1-16) 3.2 (0.2-21) NS
Median follow up (range)
in weeks
31 (1-212) 52 (10-134) NS
N (%) N (%)
Sex
Male 19 (63) 14 (43)
Female 11 (37) 16 (57) NS
Indication¶
Malignant 10 (33) 11 ( 37)
Non-malignant 20 (67) 19 (63) NS
HLA-disparity§
Matched 19 (63) 13 (43)
Mismatched 11 (37) 17 (57) NS
Number of tx
First tx 28 (93) 27 (90)
Second tx 2 (7) 2 (7)
Third tx 0 1 (3) NS
TCD
No 23 (77) 30 (100)
Yes 7 (23) 0 .01
Donor
Family 9 (30) 5 (17)
Un-related 21 (70) 25 (83) NS
Source
BM 17 (58) 13 (44)
CB£ 5 (17) 16 (53)
PBSC 8 (27) 1 (3) .02
Conditioning
Bu/Cy/Mel 6 7
Bu/Cy/VP16 5 6
Bu/Cy (1Flud) 16 (13) 15 (12)
Risk on VOD
No 16 (53) 13 (44)
Yes 14 (47) 17 (57) NS
TCD indicates Tcell depletion (CD31 cell in graft ranged from 104
to 107/kg); HSCT, hemopoietic stem cell transplantation; VOD,
Veno occlusive disease; HLA, human leukocyte antigen; BM,
bone marrow; CB 5 cord blood; PBSC 5 peripheral blood
stem cells, NS 5 not significant; CY, cyclophosphamide; Mel,
melphalan; Flud, fludarabine.
¶Malignant disease was subdivided (BUPO vs. BudtIV) in ALL (5 vs.
4),MDS (4 vs. 5), Anaplastic Lymphoma (0 vs. 1), AML (1 vs. 1).Non-
malignant was subdivided in immune deficiencies (7 vs. 7), including
Hemophagocytic Lympho-Histiocytosis (HLH: 0 vs. 4), inborn errors
of metabolism (9 vs. 9: including mucopolysaccharidosis, a-mannosi-
dose, metachromatic leukodystrophy, GM1 gangliosidosis, purine
nucleoside phosphorilase deficiency), Fanconi anemia (2 vs. 2), thalas-
semia (1 vs. 0) and Glanzmann (1 vs. 0).
§Matched was defined when either 10 of 10 molecularly typed allels
were matched for bone marrow or PBSC or 6 of 6 for CB based
on Rubinstein criteria. Within the mismatched BM/PBSC group
(n 5 8) 6 were 9/10 matched and 2 were 8/10 matched. Within
the mismatched group (n 5 20) 16 were matched 5/6 and 4 were
matched 4/6.
£Median cell dose of the CBs used was: 7.8 x 107 NC/kg (range 2.7-
20.0 x 107) and 4.5 x 105 CD341/kg (range 1.1-10.0 x 105). All cord
bloods were unrelated.tIV. However, univariable analysis of the data showed
that these differences did not influence the primary,
nor the secondary, outcomes (Table 2).
Survival and Event Free Survival
In univariable analysis, BUdtIV was the only pre-
dictor for higher EFS and survival (OR 5 11.7, P\
.001; OR 5 4.38, P 5 .016) (Table 2 and Figure 1).
In addition, after adjustment for ‘‘prognosis in compa-
rability’’ (propensity scoring technique), BudtIV re-
mained a predictor for higher EFS and survival (OR 5
18.1, P \ .001; OR 5 6.03 P 5 .016). Initial donor
cell engraftment was found in 100% of patients treated
with BUdtIV in comparison to 83% in the BUPO
group. In the BUdtIV group, 2 patients became mixed
chimeric after 2 months, resulting in graft-failure/
relapse (HLH patient who received second transplant)
or relapse (ALL patient). All patients who are alive
have maintained full donor chimerism. In the BUPO
group, 10 patients had graft failure (for which 7 were
retransplanted) and 1 patient died early before engraft-
ment. In the BUPO group, two patients who are alive
have stable mixed chimerism.
In the BUPO group, graft failure was more
frequently seen in the patients with nonmalignant
disease: (1 thallassemia, 4 mucopolysaccharidose, 1
metachromatic leukodystrophy, osteopetrosis, variant
Blackfan-Diamond anaemie, and common variable
immunodeficiency. 9 of 20 patients with nonmalignant
disease had graft failure versus 2 out of 10 in the malig-
nant group (1 ALL, 1 MDS: OR 5 4.10, CI 95% 5
0.69-23.95, P 5.12). On the other hand, TRM
appeared to be higher in the malignant group, was
5 of 10, versus 5 of 20 in the nonmalignant group.
The 2 patients in the BUdtIV group who had a graft
failure, suffered from ALL and HLH.
In the BUdtIV group, 6 patients died (of whom 1
after second transplant): 1 from a relapse; 1 Epstein-
Barr virus-associated posttransplant lymphoprolifera-
tive disease; 3 from multiorgan failure; and 1 from
GVHD. In the oral Bu group, 14 patients died (of
whom5after second transplant): 2 from relapse/disease
progression; 2 from acute cardiac problems; 4 from
multiorgan failure; 3 from GVHD; 2 from (viral)
disease; and 1 from idiopathic pneumonia syndrome.
Treatment-related Toxicity
VODoccurred significantly more frequently in the
BUdtIV group than in the BUPO group, as shown in
Table 3 (OR 5 3.76, P 5 .044) (Table 3a). The pa-
tients who developed VOD (all mild to moderate:
Bearman grade 2), were successfully treated with defib-
rotide. VOD did not influence the primary end points.
The number of patients who were classified as having
an increased risk to develop VOD, was similar in
both groups (Table 1). Of all patients, 51% had an
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Event-Free Survival Survival
N total N % OR 95%-CI p-value N % OR 95%-CI p-value
Overall 60 33 55 40 67
Age 60 0.99 0.9-1.1 .773 0.92 0.8-1.0 .134
Sex
Male 32 16 50 1 21 66 1
Female 28 18 64 1.27 0.6-5.1 .267 20 71 1.31 0.4-3.9 .630
Indication
Malign 21 13 62 1 10 48 1
Non malign: 39 21 54 0.85 0.3-2.5 .773 28 71 1.94 0.6-5.9 .245
HLA-disp.
Matched 32 19 59 1 22 68 1
Mismatched 28 15 54 0.79 0.3-2.2 .789 19 66 0.96 0.3-2.9 .941
TCD
No 53 32 60 1 36 53 1
Yes 7 2 29 0.26 0.0-1.5 .130 5 71 1.18 0.2-6.7 .852
Donor
Family 14 6 43 1 8 57 1
Unrelated 46 28 61 2.1 0.6-7.0 .238 33 72 1.90 0.6-6.6 .308
Source
BM 30 19 63 1 21 70 1
CB 21 12 57 0.77 0.3-2.4 .656 15 71 1.07 0.31-3,66 .912
PBSC 9 3 33 0.29 0.1-1.4 .122 5 56 0.54 0.1-2.5 .424
Conditioning
BUPO 30 9 30 1 16 53 1
IVdtBU 30 25 83 11.7 3.4-40 \.001 25 83 4.38 1.3-15 .016
Acute-GVHD
No 52 28 54 1 35 67 1
Yes 8 6 75 2.57 0.5-14 .274 6 75 1.46 0.3-8.0 .665
VOD
No 45 25 56 1 30 67 1
Yes 15 9 60 1.20 0.4-3.9 .764 11 73 1.38 0.4-5.0 .632
OR indicates odd ratio; CI, confidence intervals; TCD, T-cell depletion; VOD, Veno occlusive disease; HLA disp, human leukocyte antigens
disparity; GVHD, graft versus host disease; BM, bone marrow; CB, cord blood; PBSC, peripheral blood stem cells; N, amount; BUPO, oral
busulfan; BUdtIV, An intravenous dose of busulfan, combined with drug targeting based on therapeutic drug monitoring.increased risk to develop VOD. Of this high-risk
group within BUdtIV, 32% developed VOD, whereas
17% of patients without risk factors, developed VOD.
6 of 7 patients (87%) developed VOD after a condi-
tioning regimen of BUdtIV in combination with cy-
clophosphamide and Mel, whereas only 5 of 23
(22%) other patients in the BUdtIV group developed
VOD (OR 5 3.62, CI 95% 5 0.98-13.42, P 5 .054)
No significant difference in GvHD between the
two Bu groups was found (Table 3b). Patients with
nonmalignant disease showed a lower incidence of
GVHD than patients treated for malignant diseases
(OR5 0.15, P5 .028). Multivariable analysis that pa-
tients who develop VOD, also more frequently devel-
oped acute GVHD (OR 5 12.7, P 5 .008).
Therapeutic Drug Monitoring
The results of dose targeting based on TDM are
shown in Table 4. Figure 2 shows a representative con-
centration-time curve of BUdtIV. In all but 1 patient,
the AUC was determined after the first dose. For one
patient, the laboratory method to determine the con-
centration of the busulfan monsters was not availableat that time. As mentioned above, this patient was ex-
cluded from analysis. In all but 1 patient, trough con-
centrations were below the limit of detection (\50 mg/
l). One patient showed a trough concentration 24
hours after the first dose of 90 mg/l. In 10 patients,
no dose adjustment was needed; in 19 patients a dose
decrease was made and in 1 patient a dose increase
was made.
In patients UPN 12 and 17, the dose was reduced
.25% on the AUC of day 1. The analysis at day 4 of
these 2 patients showed that the AUC had declined
more than expected. The AUC at day 4 was 30% lower
than the target AUC. These patients showed a cumula-
tive AUC of 60.158 mg*h/l, in comparison to a median
of 79,614 mg*h/l recorded in the other patients. These
2 patients became mixed chimeric after 2 months re-
sulting in graft-failure and relapse. A third patient
(with a combined immunodeficiency), whose AUC at
day 4 was out of range, received a total AUC of
65,600 mg*h/l after a dose reduction of 20%. This pa-
tient is alive and engrafted (with chronic GVHD
[cGVHD]). After this observation, the dose adjust-
ment policy was changed: when a dose adjustment
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Figure 1. Kaplan-Meier Curve of event free survival (a), survival (b)
and graft failure (c) after HSCT with iv-targeted-Bu versus oral Bu..25% was suggested, further dose adjustments based
on TDM at day 3 and 4 were performed.
DISCUSSION
This study compared the outcomes of HSCT in
children, after a preparative chemotherapy-regimen
including i.v. Bu with TDM with the current practice
of untargeted oral Bu (BUPO). TDMafter a once daily
dose of intravenous Bu (BUdtIV) resulted in a signifi-
cantly better survival and EFS, in comparison to
BUPO. Also, after adjustment, using propensity score
techniques to adjust for prognosis in comparability,
this association remained significant. BUdtIV was as-
sociated with VOD mainly in patients receiving Bu
plus mel in their conditioning. Patients who developed
VOD, also developed acute GVHD more frequently.
In addition, TDM of Bu in clinical practice was feasi-
ble.
A randomized, blinded, controlled trial would be
the best instrument to test the 2 therapies. Practically
this was not possible for this study within the UMCU.
The use of hard clinical endpoints diminished assessor
bias as much as possible. In addition, the inclusion of
patients was performed in the same period for both
treatment groups. All patients were treated similarly, re-
garding indication associated conditioning regimens
and supportive care given. Patient characteristics in
both groups were similar, with the exception of two var-
iables: TCD was used more often in the BUPO group
and CB was used more often in the BUdtIV. These dif-
ferences, however, did not influence the primary, nor
the secondary, outcomes. Probably the relatively high
CD31 dose after TCD, is the reason why TCD did
not influence the end points. By using propensity scor-
ing techniques, adjustments were made for prognosis in
comparability (ie, the chance to get a certain treatment:
BUPO vs BUdtIV). The results from this analysis sug-
gest that groups were comparable. However, the wide
range of diseases, preparative regimens, and cell sources
utilized in this relatively small cohort of children, re-
mains a limitation in this study.
Theoretically, BUdtIV has advantages over
BUPO: 1) the AUC of i.v. Bu is more predictable,
due to the variability in oral absorption of Bu, which
differ in children from 20% to 100%, and the circum-
vention of the first-pass hepatic effect after an i.v. dose
[43]; 2) the possibility of its administration once daily,
whereas BUPO may only be administered every 6
hours, mainly because only 2 mg tablets are available.
A once daily dose is much more convenient for both
caregivers and patients. Fewer infusions are needed
which means: there is less burden for the patient; it is
easier for the nursing personnel; and there is a smaller
chance of administration errors. Possibly, single ad-
ministration leads to a better penetration of poorly vas-
cularized parts of the body, resulting from a higher
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VOD GVHD
N total N % OR 95% CI P-Value N % OR 95% CI P-Value
Overall 60 14 23 8 13
Age 60 1.05 0.4-1.2 .422 1.06 0.9-1.2 .370
Sex
Male 32 7 22 1 3 9 1
Female 28 8 28 1.43 0.4-4.6 .551 5 18 2.10 0.4-9.7 .342
Indication
Malign 21 8 38 1 6 298 1
Non malign 39 7 18 0.40 0.1-1.3 .128 2 5 0.15 0.03-0.8 .028
HLA-disp.
Matched 32 10 31 1 7 22
Mismatched 28 5 18 0.48 0.1-1.6 .237 1 4 0.13 0.02-1.2 .067
TCD§
No 53 14 26 1 7 13 1
Yes 7 1 14 0.46 0.05-4.2 .495 1 14 1.10 0.1-11 .937
Donor
Family 14 5 35 1 2 145 1
Unrelated 46 10 21 0.50 0.1-1.8 .295 6 13 0.90 0.2-5.0 .905
Source
BM 30 8 27 1 6 20 1
CB£ 21 4 19 0.64 0.2-2.5 .53 0 0 0.23 0.03-2.1 .194
PBSC 9 3 33 1.38 0.3-6.8 .69 2 22 1.37 0.2-8.7 .74
Conditioning
BUPO 30 4 13 1 3 10 1
IVdtBU 30 11 37 3.76 1.04-14 .044 5 17 1.80 0.4-8.3 .452
Acute-GVHD
No 52 9 17 1
Yes 8 6 75 14.3 2.5-83 .003
VOD
No 45 2 4 1
Yes 15 6 40 14.3 2.5-83 .003peak concentration [44]. As mentioned in the intro-
duction, the lower exposure period to Bu in a once
daily schedule might be associated with reduced toxic-
ity. In addition to i.v. administration of Bu, dose tar-
geting might further have optimized the outcome. In
light of the more predictable kinetics with i.v.adminis-
tration, TDM of i.v. Bu seems therefore to be more ra-
Table 3b. Multivariable Predictors for the Development of VOD and
Acute GVHD
Multivariate
analysis VOD GVHD
OR 95% CI P-Value OR 95% CI P-Value
BUdtIV 4.07 0.9-18 .060
Acute-GVHD 15.4 2.4-99 .004
VOD 12.7 1.9-84 .008
Indication 0.23 0.03-1.6 .131
Match 0.19 0.02-2.0 .165
OR indicates odds ratio; CI, confidence interval; TCD,T-cell deple-
tion; VOD, Veno occlusive disease; HLA disp, human leukocyte
antigenes disparity; GVHD, graft versus host disease; BM, bone
marrow; CB, cord blood; PBSC, peripheral blood stem cells;
BUPO, oral busulfan; BUdtIV, intravenous once daily busulfan,
combined with drug targeting based on therapeutic drug
monitoring.tional than dose targeting of oral Bu. Secondly, it was
easier to perform TDM on a once daily dosing sched-
ule than on a 4 times daily schedule, since no
Table 4. Busulfan Pharmacokinetics
Median Mean 95% CI
AUC after first dose (mg*h/l) 20,211 20,946 18,839-23,054
AUC after 4th dose (mg*h/l) 20,313 20,313 17,236-23,237
Adjusted dose (mg/m2) 101.0 99.7 91.7-107.7
Adjusted dose (mg/m2) in
children\ 1 year (n56)
75.6 80.7 73.9-87.4
Adjusted dose (mg/kg) 4.21 4.10 3.78-4.88
Total AUC (mg*h/l)§ 79,270 79,940 77,443-82,437
Total dose/day (mg/m2) 104.6 103.1 96.1-110.1
Total dose (mg/m2) in children
\ 1 year (n56)
76.3 81.8 75.6-88.0
The analyses of the two Fanconi anemia patients are excluded. These
patients received one third of the dose of other patients.
AUC indicates area under the curve; Sd, standard deviation.
§In these AUC calculations, 2 patients are included, who received
a .25% dose reduction based on the AUC of day 1. The analysis
at day 4 of these patients showed that the AUC had declined more
than expected (AUC day 4 were 11,390 and 12,594 mg*h/l). Both
patients had a graft failure after 2 months. After exclusion these
patients, the mean total AUC is: 79,614 mg*h/l (CI 95%: 77,073-
81,264 mg*h/l).
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tionally, individualization of BUPO dosing based on
TDM could have been jeopardized by problems inher-
ent to the use of the oral form, like vomiting, incom-
plete absorption, and unpredictable bioavailability
between administrations. These problems occur espe-
cially in the very young. This study included many
young patients, 22 patients were younger than 3 years.
In most previous studies, i.v. Bu (like oral Bu) was
administered 4 times daily. Results from the studies us-
ing the same AUC per day, divided in 4 doses, were in
line with the results of this study: approximately 90%
of patients had complete donor cell chimerism versus
100% in our study; and EFS ranged from 65% to
85% as compared to 83% in our study [9-11]. The pa-
tient populations, however, were different. Our study
included a high percentage (52%; IEM, MDS,
HLH) of indications known to be associated with
high graft-failure/relapse rates as compared to 5%
and 40% in other studies [9,11].
Patients with non-malignant disorders (eg IEM) in
general have history of allograft resistance. In the
BUPO group, the patients with non-malignant dis-
eases, noted a large incidence of primary or secondary
graft failures (45%), in line with other studies [1], while
a trend to less graft failure was seen in the malignant
indications in this study. In the BudtIV group, on the
other hand, no difference in graft-failure/relapse was
seen (only 2 / 30). This study shows that i.v. Bu using
TDM improved mainly the outcome of patients with
a high risk for graft failure. These results are in line
with other studies in which similar patients with simi-
lar indications were treated (eg, in patients with
Hurler’s syndrome); BUdtIV also showed improved
EFS in comparison to BUPO (EFS: 53% versus
87%) [45] as well as with the results reported by the
LeidenUniversityMedical Center (a comparable pedi-
atric HSCT ward). They treated another 14 patients
with the same BUdtIV protocol as this study’s protocol
(AUC targeted; once daily). These patients (7 malig-
Figure 2. Example of blood concentrations in a patient.nant {6 MDS, 1 ALL} and 7 nonmalignant) showed
similar results: 79% (11/14) EFS and overall survival
(OS), 100% engraftment, no relapses/graft failures
and 42% VOD (mainly in the Bu/Cy/Mel group).
Because of the narrow therapeutic window, the tar-
get AUC seems to be important for reduction of toxic-
ity and graft-failure. This was once again indicated by
a recent study using a once daily dose of i.v. Bu in chil-
dren [12]. This study used a target AUC of 15,600
mg*h/l (3800 mmol*min/l) for a similar distribution of
indications as in our study. In this study by Zwaveling
et al, only 55% of patients were alive and engrafted
(EFS) after first procedure, compared to .80% in
this study. However, EFS depends on many factors,
which makes precise comparison difficult.
In contrast to what this study’s hypothesis, i.v. Bu
was associated with more cases of VOD. Also, in com-
parison to a similar studies, (ie once daily, same AUC)
in adults this incidence was high: 37% of the children
in this study versus 8% or 1% of the adult patients in
other studies developed VOD [27,28]. This difference
might be explained by the fact that other criteria (the
Jones criteria) were used to define VOD [46]. In a pedi-
atric study using once daily i.v. Bu an incidence of
VOD of only 6% was found [12]. This study, however,
used a lower target AUC. Because a high AUC of Bu is
correlated to a higher risk to develop VOD [2,13-15],
these results cannot be compared to our results. The
studies with Bu divided over 4 doses per day with the
same target AUC per day, showed an incidence of
VOD of 0% to 25% [9-11]. Only the study of
Zwaveling et al showed a similar incidence of VOD
(25% of patients) and used similar criteria to define
VOD as in our study [11]. An alternative reason for
the high incidence of VOD could be that our study
population was at quite high risk for the development
of VOD (50% at risk based on conditioning/indica-
tion). The higher frequency of VOD was mainly ob-
served in the patients also receiving Mel as part of
a myelo-ablative conditioning. 87% of patients who
used BUdtIV and Mel developed VOD. Mel probably
makes the conditioning more toxic and the patients
more vulnerable to develop VOD. In most other stud-
ies, other than the study of Zwaveling et al patients did
not receive Mel [9,11,27,28]. In patients at risk of de-
veloping VOD, reports show that 30-40% of patients
develop this side effect [40]. This incidence is similar
to our results (excluding those patients who received
Bu 1 Mel). Another explanation for the higher inci-
dence of VOD might be the higher peak levels
achieved with once daily dosing. Possibly the peak
level rather than the exposure over time is more critical
for the development of VOD. However, a recent study
in adults by Ryu et al. [29] in which adult patients were
randomized between the same dose of Bu divided in 4
times daily and a once daily dose, showed nomajor dif-
ferences in effect nor side effect [47].
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patients is of concern. However, VOD did not influ-
ence the primary endpoints and was relatively easy to
manage with the use of defibrotide. Because of the
high engraftment rate in this patients group with
‘‘high-risk patients’’ for graft-failure, we believe that
the higher incidence of VOD after once daily i.v. Bu
dosing, seems to be an acceptable side effect.
Because VOD was seen more often in the Bu/Cy/
Mel group, it might be speculated that this condition-
ing is too toxic with a total AUC of approximately
80,000mg*h/l for Bu. In the past, Mel was added to
Bu (oral without TDM), Cy in theMDS group, mainly
because of the higher graft-failure rates and because
Mel showed to be a valuable drug in AML [48].
MDS sometimes transforms into AML. With an opti-
mized Bu exposure using intravenous Bu with TDM,
addition of Mel may not be necessary to overcome
graft rejection or relapses in patients with MDS.
Dose de-escalation studies (either reduce the target
AUC of Bu or the dose Mel) might be necessary. Ran-
domized studies comparing once daily dosed Bu versus
the conventional 4 daily dosed Bu targeting for the
same AUC, might be of interest to get answer on var-
ious questions raised above.
The occurrence of GVHD did not differ signifi-
cantly between the two groups. GVHD was seen
more frequently in patients with malignant diseases.
This is probably associated with the amount of im-
mune suppression after HSCT, as lower levels of im-
munosuppression were acceptable to allow some
graft versus leukemia (GVL) effect. (CSP target trough
concentration is generally 0.1-0.15 mg/l in malignant
diseases and 0.2-0.25 mg/l in non-malignant disease
and depends on risk qualification.) An association be-
tween VOD and GVHD was found in this as well as
in other studies [39,49]. Probably both the treatment
of Bu and alloreactivity contribute to the development
of VOD.
The results of day 1 showed a variation in pharma-
cokinetics of Bu between individuals. The results show
that TDM was and remains needed. The variation in
PK, especially when large adjustments are made, indi-
cates that TDM remains necessary in this population,
at least until a better predictive model is available.
There is some concern regarding the pharmacokinetics
as a one-compartment model in this study. This model
was based on earlier studies in which the dose of Bu was
lower than the dose used in this study [2,11,50]. Phar-
macokinetic data of Bu of a dose of 120 mg/m2 were
not available beforehand. A deviation of the model
was shown in 2 patients who received a dose reduction
of.25% after TDM. A further analysis of the data will
clarify this inconsistency. These 2 patients developed
graft failure. The total AUC in these patients was ap-
proximately 60.000 mg*h/l. As shown in the study of
Zwaveling et al. a total AUC of 62.400 mg*h/l. was asso-ciated with early graft rejection in 25% of the patients
[12]. Excluding these 2 patients, the mean total AUC
was 79,614 mg*h/l. This AUC was significantly higher
than the target of 70,000 mg*h/l (17,050 mmol*min/l).
The results of this study are therefore associated with
this relatively high total AUC.
The patients younger than 1 year received a smaller
dose per m2 in comparison to patients older than 1
year. This dosing schedule remained similar after
TDM. Further research into the pharmacokinetics of
Bu will be performed in order to increase the knowl-
edge of the optimal doses of Bu in patients of all ages
as well as to study whether distinctive indication
groups, like patients with malignant diseases or recip-
ients of HLA-matched grafts could receive a lower tar-
geted AUC, in order to optimize EFS and to minimize
side effects.
In conclusion, this study showed that once daily
dosing of i.v. Bu, after dose adjustment to a total
AUC of 79,614 mg*h/ (19,395 mmol*min/l), was associ-
ated with higher survival and EFS rates in a group of
patients known to be associated with high graft fail-
ure/relapse rates. The higher incidence of VOD (in
37% of patients) might be a concern, although VOD
was easy to treat. Melphalan as a risk factor in develop-
ing VOD in combination with Bu, will be studied into
more detail for instance with dose de-escalation of
Mel. Randomized studies and distinction between sub-
groups such as malignant and nonmalignant diseases,
would increase our knowlegde of i.v. Bu in childern.
Although once-daily dosing with TDM was feasible
and convenient for caregivers, additional studies are
needed to fine tune the pharmacokinetic/pharmacody-
namic model to be used, resulting in an optimal dose
and a better prediction of the target AUC for all pedi-
atric age categories. These results strongly suggest that
i.v. Bu, using TDM is preferable over oral Bu, in chil-
dren undergoing allogeneic SCT, especially in those at
high risk for graft failure/ relapse.
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